Bioanalysis
Understanding Vaccines and Immunization
Your Immune System is your Body’s Defense Against Infection
You may already know that vaccines wor
Quantitation of a PEGylated Human Parathyroid Hormone (1-34) Analog in Rat Plasma Using a Hybrid Immunoaffinity Bottom-Up LC-MS/MS Assay
The Application of Light-Absorbing Photostabilizers for the Determination of Protoporphyrin IX in Human Plasma by LC-MS/MS
Overcoming Recovery Challenges in Hemolyzed Samples for the Determination of Propafenone and 5-Hydroxy Propafenone by LC-MS/MS
Method Development for the Detection of Exicure’s AST-008 in Human Plasma
A Lesson in Adaptability for the Determination of Rifampin
ISSUE NO. 8 — Bioanalytical Challenges Encountered when Developing ADA Assays
Following the approval in 1986 of Orthoclone OKT3, the first therapeutic monoclonal antibody product, a class of new protein-based therapeutic drugs was introduced and became the dominant product class within the biopharmaceutical market.
Today, several monoclonal antibodies have been approved for the treatment of a variety of diseases, ranging from those that target orphan disease indications with a small patient population, to those that target much larger patient populations and demographics, such as for oncology, asthma, and rheumatoid arthritis.
In Issue 8 of The Altascientist, we explore the role of anti-drug antibodies (ADAs) in therapeutic development, their impact on efficacy, and detection strategies, including:
- Challenges encountered in ADA assays
- Cell-based or non-cell-based assays to measure neutralization
- How Altasciences can help
ISSUE NO. 4 — Key Considerations for Biosimilar Clinical Pharmacology Studies
Selective Quantitation of 1,3-Propanediol in Dog Plasma Using Differential Ion Mobility Spectrometry
Patient Centricity — taking care of our most valuable asset!
“Patient centricity” is the process of designing a service or solution around the patient; more specifically, it is collectively defined as “Putting the patient fi